CHOICE OF TARGETED DRUG FOR SECOND-LINE METASTATIC COLON CANCER CHEMOTHERAPY

Onkologičeskaâ Koloproktologiâ. 2015;5(1):37-42 DOI 10.17650/2220-3478-2015-1-37-42

 

Journal Homepage

Journal Title: Onkologičeskaâ Koloproktologiâ

ISSN: 2413-0583 (Online)

Publisher: ABV-press

Society/Institution: Society of Professionals in Oncological Coloproctology (Russia) 

LCC Subject Category: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens

Country of publisher: Russian Federation

Language of fulltext: Russian

Full-text formats available: PDF

 

AUTHORS

M. Yu. Fedyanin (N.N. Blokhin Russian Cancer Research Center)
A. A. Tryakin (N.N. Blokhin Russian Cancer Research Center)
S. A. Tjulandin (N.N. Blokhin Russian Cancer Research Center)

EDITORIAL INFORMATION

Double blind peer review

Editorial Board

Instructions for authors

Time From Submission to Publication: 8 weeks

 

Abstract | Full Text

<p><em>Durin</em><em>g the last 5 years the prognosis of metastatic colorectal cancer patients improved significantly. This results not only from increased amount of surgery for metastatic disease and use of targeted drugs in first-line treatment, but also from increased number of patients receiving effective second- and third-line chemotherapy. Currently a minimum of 7 treatment groups can be distinguished depending on prior first-line chemo- and targeted therapy. Consequentially we have less evidence-based data to guide the treatment choice for next treatment lines. This article discusses the choice of targeted drugs in combination with second-line chemotherapy.</em></p>